मूलभूत आँकड़े
| LEI | 9845004D8538BT8JF626 |
| CIK | 1124524 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cryoport, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-34632 NOTIFICATION OF LATE FILING CUSIP NUMBER 229050307 (Check one): ◻ Form 10-K ◻ Form 20-F ◻ Form 11-K ⌧ Form 10-Q ◻ Form 10-D ◻ Form N-CEN ◻ Form N-CSR For Period Ended: June 30, 2025 ◻ Transition Report on Form 10-K ◻ Transition Report on Form 20-F ◻ Transition Report on Form 11-K ◻ Transit |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001 |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 CRYOPORT, INC. |
|
| August 6, 2025 |
Cryoport Reports Second Quarter 2025 Financial Results Exhibit 99.1 Cryoport Reports Second Quarter 2025 Financial Results § Second quarter revenue increased 14% year-over-year to $45.5 million § Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million § Life Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue § Launched strategic partnership agreement with the DHL Gr |
|
| June 13, 2025 |
Cryoport, Inc. and Subsidiaries Unaudited Pro Forma Condensed Consolidated Financial Information Exhibit 99.2 Cryoport, Inc. and Subsidiaries Unaudited Pro Forma Condensed Consolidated Financial Information On June 11, 2025, the Company completed the previously disclosed divestiture of its CRYOPDP Business to designated affiliates of DHL Supply Chain International Holding B.V. (“DHL”) for $133.0 million. Pursuant to the terms of the Agreement, DHL acquired 100% of the capital stock and voting |
|
| June 13, 2025 |
Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group Exhibit 99.1 Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group NASHVILLE, Tennessee, June 12, 2025 - Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a focus on regenerative medicine, today announced the completion of the previously disclosed divestiture of its |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 CRYOPORT, INC. |
|
| June 10, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 CRYOPORT, INC. |
|
| May 30, 2025 |
EXHIBIT 1.01 Cryoport, Inc. Conflict Minerals Report for the Year Ended December 31, 2024 This report for the year ended December 31, 2024 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (the “SEC”) to implement reporting and disclosure requirements related to conflict minerals |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) Cryoport, Inc. 112 Westwood Place, Suite 350 Brentwood, TN 37027 (Addr |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 00 |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 CRYOPORT, INC. |
|
| May 7, 2025 |
Cryoport Reports First Quarter 2025 Financial Results Exhibit 99.1 Cryoport Reports First Quarter 2025 Financial Results · Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year · Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year · Supporting 711 global clinical trials as of March 31, 2025 · Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025 NASHVILLE, Tennessee, Ma |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under §240. |
|
| April 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Under §240. |
|
| March 31, 2025 |
Exhibit 2.1 SALE AND PURCHASE AGREEMENT by and between THE SELLERS and THE purchaser with respect to THE ACQUISITION OF THE SHARES OF PDP Courier Services INC. ADVANCED THERAPY LOGISTIC AND SOLUTIONS SAS COURIER POLAR EXPRES S.L. CRYO EXPRESS GmbH 31 MARCH 2025 TABLE OF CONTENTS 1. DEFINITIONS 4 2. PRINCIPLES OF CONSTRUCTION 28 3. Sale AND PURCHASE 29 4. Purchase price of the Transferred Shares an |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 CRYOPORT, INC. |
|
| March 31, 2025 |
Exhibit 99.2 Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET NASHVILLE, Tennessee, March 31, 2025 - Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in supply chain solutions for the life sciences sector, today announced that the Company will host an investor call today, Monday, M |
|
| March 31, 2025 |
Exhibit 99.1 Press release DHL Group acquires CRYOPDP from Cryoport to strengthen “DHL Health Logistics” Ÿ DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL’s capabilities in specialty pharma logistics and supports Group’s 2030 strategy to become a leader in life science |
|
| March 7, 2025 |
Form of Stock Option Agreement Issued by Cryoport, Inc. to certain employees on May 7, 2015. Exhibit 10.17 STOCK OPTION AGREEMENT This Stock Option Agreement (“Agreement”) is between Cryoport, Inc. (“Company”) and (the “Optionee”), and is effective as of , 2015 (“Grant Date”). AGREEMENT In consideration of the mutual covenants and conditions hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and th |
|
| March 7, 2025 |
As filed with the Securities and Exchange Commission on March 7, 2025 As filed with the Securities and Exchange Commission on March 7, 2025 Registration No. |
|
| March 7, 2025 |
EXHIBIT 21 SUBSIDIARIES OF CRYOPORT, INC. AND JURISDICTION OF INCORPORATION OR ORGANIZATION Cryogene, Inc. Texas Cryoport Systems, LLC California MVE Biological Solutions US, LLC Delaware Cryoport Netherlands BV The Netherlands Cryoport France, SAS France Cryoport Japan GK Japan Cryoport UK Limited United Kingdom Cryoport Belgium SA Belgium Cryoport Germany, GmbH Germany Bluebird Express, LLC New |
|
| March 7, 2025 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Cryoport, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per |
|
| March 7, 2025 |
Cryoport, Inc. Insider Trading Policy. Cryoport, Inc. Insider Trading and Tipping Policy 1.0 PURPOSE This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Cryoport, Inc. (the “Company”) and the handling of confidential information about the Company, its subsidiaries and the companies with which the Company does business. The Company’s Board of Directors has adopted this Policy |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-346 |
|
| March 4, 2025 |
Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results § FY 2024 revenue of $228.4 million, in-line with company guidance § Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year § Supporting a record total of 701 global clinical trials as of December 31, 2024 NASHVILLE, Tennessee, March 4, 2025, - Cryoport, Inc. (NASDAQ: CYRX) (Cryo |
|
| March 4, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 CRYOPORT, INC. |
|
| November 14, 2024 |
CYRX / Cryoport, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0090934-4sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 4)* Cryoport Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 229050307 (CUSIP Number) Edd |
|
| November 14, 2024 |
CYRX / Cryoport, Inc. / ALGER ASSOCIATES INC - CRYOPORT, INC. Passive Investment SC 13G 1 d892202dsc13g.htm CRYOPORT, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cryoport, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| November 13, 2024 |
CYRX / Cryoport, Inc. / CADIAN CAPITAL MANAGEMENT, LP Passive Investment SC 13G/A 1 formsc13ga-cryoport.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cryoport, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 229050307 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 CRYOPORT, INC. |
|
| November 7, 2024 |
Cryoport Reports Third Quarter 2024 Financial Results Exhibit 99.1 Cryoport Reports Third Quarter 2024 Financial Results § Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year § Supported a record total of 691 global clinical trials as of September 30, 2024 § Company reaffirmed full year 2024 revenue guidance of $225 to $235 million NASHVILLE, Tennessee, November 7, 2024, - Cryopo |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| October 16, 2024 |
CYRX / Cryoport, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 CYRXSC13GA.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) CRYOPORT, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 229050307 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box |
|
| September 3, 2024 |
CYRX / Cryoport, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CRYOPORT, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 229050307 (CUSIP Number) AUGUST 27, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001 |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 CRYOPORT, INC. |
|
| August 6, 2024 |
Exhibit 99.1 Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes · $200 million repurchase program authorized to repurchase common stock and/or convertible notes · Repurchasing approximately $160 million of 0.75% Senior Notes due in 2026 at an 11.5% discount to par value · Principal balance reduced to approximately $186.2 million NASHVI |
|
| August 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 CRYOPORT, INC. |
|
| August 6, 2024 |
Cryoport Reports Second Quarter 2024 Financial Results Exhibit 99.1 Cryoport Reports Second Quarter 2024 Financial Results § Revenue improved sequentially across all businesses § Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially § A record total of 684 global clinical trials supported as of June 30, 2024 § Cost reduction initiatives anticipated to result in approximately $22 million of annualized cost savings and |
|
| June 14, 2024 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Cryoport, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per sha |
|
| June 14, 2024 |
As filed with the Securities and Exchange Commission on June 14, 2024 As filed with the Securities and Exchange Commission on June 14, 2024 Registration No. |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) Cryoport, Inc. 112 Westwood Place, Suite 350 Brentwood, TN 37027 (Addr |
|
| May 30, 2024 |
EXHIBIT 1.01 Cryoport, Inc. Conflict Minerals Report for the Year Ended December 31, 2023 This report for the year ended December 31, 2023 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (the “SEC”) to implement reporting and disclosure requirements related to conflict minerals |
|
| May 22, 2024 |
Exhibit 10.1 Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended by the First Amendment, the Second Amendment, and the Third Amendment effective May 17, 2024) ARTICLE 1 ESTABLISHMENT, PURPOSE, EFFECTIVE DATE, EXPIRATION DATE 1.1 Establishment; Impact on Prior Plans. Cryoport, Inc. (the “Company”) hereby establishes the “Cryoport, Inc. 2018 Omnibus Equity Incentive Plan” (the “Pl |
|
| May 22, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 CRYOPORT, INC. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 00 |
|
| May 7, 2024 |
Cryoport Reports First Quarter 2024 Financial Results Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results § Q1 2024 revenue of $54.6 million § 9% year-over-year increase in Commercial Cell & Gene Therapy revenue § 9% year-over-year increase in BioStorage/BioServices revenue § A total of 675 global clinical trials supported as of March 31, 2024 § $242 - $252 million full year 2024 revenue guidance reiterated NASHVILLE, Tennessee, May 7, |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 CRYOPORT, INC. |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under §240. |
|
| April 3, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Under §240. |
|
| March 13, 2024 |
Cryoport, Inc. Clawback Policy Exhibit 97 CRYOPORT, inc. Clawback Policy The Board of Directors of Cryoport, Inc. (the “Board”) has determined that it is in the best interests of Cryoport, Inc. (the “Company”) and its shareholders to adopt this Clawback Policy (the “Policy”). In addition to any amounts that are to be recovered on behalf of the Company by the Securities and Exchange Commission pursuant to Section 304 of the Sarb |
|
| March 13, 2024 |
Employment Agreement dated February 19, 2024 between the Company and Edward Zecchini. Exhibit 10.11 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into effective as of February 19, 2024 (the “Effective Date”) by and between Cryoport, Inc., a Nevada corporation (the “Company”), and Edward Zecchini (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.” RECITAL |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-346 |
|
| March 13, 2024 |
EXHIBIT 21 SUBSIDIARIES OF CRYOPORT, INC. AND JURISDICTION OF INCORPORATION OR ORGANIZATION Cryogene, Inc. Texas Cryoport Systems, LLC California MVE Biological Solutions US, LLC Delaware Cryoport Netherlands BV The Netherlands Cryoport France, SAS France Cryoport Japan GK Japan Cryoport UK Limited United Kingdom Cryoport Belgium SA Belgium Cryoport Germany, GmbH Germany Cell&Co, SAS France Bluebi |
|
| March 12, 2024 |
Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results § FY 2023 revenue of $233.3 million, in-line with guidance § Year-over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices revenue increased 45% § Global clinical trials supported reached a record 675 NASHVILLE, Tennessee, March 12, 2024, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), a globa |
|
| March 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 CRYOPORT, INC. |
|
| February 15, 2024 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is made and entered into effective as of February 15, 2024 (the “Effective Date”) by and between Cryoport, Inc., a Nevada corporation (the “Company”), and Robert S. Stefanovich (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties,” and |
|
| February 15, 2024 |
Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is made and entered into effective as of February 15, 2024 (the “Effective Date”) by and between Cryoport, Inc., a Nevada corporation (the “Company”), and Mark Sawicki (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties,” and individu |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2024 CRYOPORT, INC. |
|
| February 15, 2024 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is made and entered into effective as of February 15, 2024 (the “Effective Date”) by and between Cryoport, Inc., a Nevada corporation (the “Company”), and Jerrell W. Shelton (“Executive”), a resident of Tennessee. The Company and Executive are hereinafter collectively referred to |
|
| February 14, 2024 |
CYRX / Cryoport, Inc. / CADIAN CAPITAL MANAGEMENT, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
CYRX / Cryoport, Inc. / ALGER ASSOCIATES INC - CRYOPORT, INC. Passive Investment Cryoport, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Cryoport, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2024 |
CYRX / Cryoport, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0086869-5sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Cryoport Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 229050307 (CUSIP Number) Edd |
|
| February 13, 2024 |
CYRX / Cryoport, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0709-cryoportinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: CryoPort Inc Title of Class of Securities: Common Stock CUSIP Number: 229050307 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule p |
|
| December 21, 2023 |
PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-251354 CRYOPORT, INC. 453,396 Shares of Common Stock 5,876,378 Shares of Common Stock issuable upon conversion of 4.0% Series C Convertible Preferred Stock $14,344,000 3.00% Convertible Senior Notes due 2025 and shares of Common Stock issuable upon conversion of the notes This prospectus relates to the offer and sale from time to tim |
|
| December 15, 2023 |
As filed with the Securities and Exchange Commission on December 15, 2023 As filed with the Securities and Exchange Commission on December 15, 2023 Registration No. |
|
| December 15, 2023 |
Power of Attorney of Linda Baddour. Exhibit 24.2 CRYOPORT, INC. POWER OF ATTORNEY The undersigned hereby constitutes and appoints Jerrell W. Shelton and Robert S. Stefanovich, and each of them singly (with full power to each of them to act alone), as her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for her and in her name, place and stead, and in any and all capaci |
|
| December 15, 2023 |
Opinion of Snell & Wilmer L.L.P. (with respect to securities under the base prospectus). Exhibit 5.3 [Snell & Wilmer L.L.P. Letterhead] December 15, 2023 Cryoport, Inc. 112 Westwood Place, Suite 350 Brentwood, TN 37027 Ladies and Gentlemen: We have acted as Nevada counsel to Cryoport, Inc., a Nevada corporation (the “Company”), in connection with the filing with the Securities and Exchange Commission (the “Commission”) of Post-Effective Amendment No. 1 to the Registration Statement on |
|
| December 15, 2023 |
As filed with the Securities and Exchange Commission on December 15, 2023 As filed with the Securities and Exchange Commission on December 15, 2023 Registration No. |
|
| December 15, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Cryoport, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities (1) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Secur |
|
| November 15, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CRYPORT, INC. (as amended and restated as of November 9, 2023) ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Annual Meeting. (a) An annual meeting of the stockholders, for the purpose of the election of directors to succeed those whose terms may expire in such year and for the transaction of such other business as may properly come before the meeting, sha |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 CRYOPORT, INC. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| November 8, 2023 |
Cryoport Reports Third Quarter 2023 Financial Results Exhibit 99.1 Cryoport Reports Third Quarter 2023 Financial Results § Third quarter 2023 commercial Cell and Gene Therapy revenue up 54% year-over-year § Supporting a record total of 670 clinical trials worldwide, with 81 in Phase 3 § Nine months 2023 revenue of $176 million § Affirms full year 2023 revenue guidance of $233 - $243 million NASHVILLE, Tennessee, November 8, 2023, - Cryoport, Inc. (NA |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 CRYOPORT, INC. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001 |
|
| August 9, 2023 |
Cryoport Reports Second Quarter 2023 Financial Results Exhibit 99.1 Cryoport Reports Second Quarter 2023 Financial Results § Second quarter revenue of $57 million, in line with previously announced preliminary results § Clinical trials supported by Cryoport increased to a record 668 global clinical trials by quarter end; a net increase of 42 new trials added year-over-year § Strong balance sheet with over $500 million in cash and short-term investment |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 CRYOPORT, INC. |
|
| July 12, 2023 |
Exhibit 99.1 Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations § Second quarter results were impacted by weaker than expected global demand for capital equipment; clinical trial start delays; and slower than expected ramps from certain clients § Second quarter revenue expected in the range of $56.5 - $57.5 million § Full year 2023 revenue now exp |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 CRYOPORT, INC. |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) Cryoport, Inc. 112 Westwood Place, Suite 350 Brentwood, TN 37027 (Addr |
|
| May 30, 2023 |
EXHIBIT 1.01 Cryoport, Inc. Conflict Minerals Report for the Year Ended December 31, 2022 This report for the year ended December 31, 2022 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (the “SEC”) to implement reporting and disclosure requirements related to conflict minerals |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 CRYOPORT, INC. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 00 |
|
| May 4, 2023 |
Cryoport Reports First Quarter 2023 Results Exhibit 99.1 Cryoport Reports First Quarter 2023 Results § Record revenue of $63 million, representing 20% growth year-over-year § Growth across all lines of business: Biopharma/Pharma revenue up 19%; Animal Health revenue up 30%; Reproductive Medicine revenue up 13% year-over-year § Commercial Cell and Gene Therapy revenue up 28% year-over-year, now supporting 82 Phase 3 clinical trials § Strong |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 CRYOPORT, INC. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under §240. |
|
| March 31, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Under §240. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 CRYOPORT, INC. |
|
| March 28, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (the “First Amendment”) is made and entered into effective as of March 24, 2023 (the “Amendment Date”) by and between Cryoport, Inc., a Nevada corporation (the “Company”), and Robert Stefanovich (“Executive”), a resident of Tennessee. The Company and Executive are hereinafter collectively referred to as the “Parties,” and in |
|
| March 15, 2023 |
Exhibit 16.1 Ernst & Young LLP 18101 Von Karman Ave. Suite 1700 Irvine, CA 92612 Tel: +1 949 794 2300 Fax: +1 949 437 0590 ey.com March 15, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated March 15, 2023, of Cryoport, Inc. and are in agreement with the statements contained in the third and fourth paragrap |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 CRYOPORT, INC. |
|
| February 28, 2023 |
EXHIBIT 21 SUBSIDIARIES OF CRYOPORT, INC. AND JURISDICTION OF INCORPORATION OR ORGANIZATION Cryogene, Inc. Texas Cryoport Systems, LLC California MVE Biological Solutions US, LLC Delaware Cryoport Netherlands BV The Netherlands Cryoport France, SAS France Cryoport Japan GK Japan Cryoport UK Limited United Kingdom Cell&Co, SAS France Cell Matters SA Belgium MVE Biological Solutions Australia Pty Li |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-346 |
|
| February 23, 2023 |
Cryoport Reports Fourth Quarter and Full Year 2022 Results Exhibit 99.1 Cryoport Reports Fourth Quarter and Full Year 2022 Results § 2022 revenue reached a record $237 million, commercial revenue up 27% year-over-year § Now supporting a record 654 global clinical trials and 10 commercial therapies § Entering 2023 with $523 million in cash and short-term investments § Revenue guidance for the full year 2023 of $270 - $290 million, up 18% year-over-year at |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 CRYOPORT, INC. |
|
| February 14, 2023 |
CYRX / CryoPort Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0081786-1sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* Cryoport Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 229050307 (CUSIP Number) Edd |
|
| February 14, 2023 |
CYRX / CryoPort Inc / ALGER ASSOCIATES INC - CRYOPORT, INC. Passive Investment SC 13G/A 1 d405876dsc13ga.htm CRYOPORT, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Cryoport, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 9, 2023 |
CYRX / CryoPort Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: CryoPort Inc. Title of Class of Securities: Common Stock CUSIP Number: 229050307 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 8, 2023 |
CYRX / CryoPort Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CryoPort Inc (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 CRYOPORT, INC. |
|
| November 3, 2022 |
Cryoport Reports Results for the Third Quarter 2022 Exhibit 99.1 Cryoport Reports Results for the Third Quarter 2022 ? Third quarter revenue of $60.5 million; nine months 2022 revenue reaches $176.9 million; Cryoport Systems? revenue up 25% year-over-year ? $530 million in cash and short-term investments ? Supporting a record 643 global clinical trials; 61 net new trials added (year-over-year) ? Entered strategic relationship with Takeda's BioLife |
|
| October 11, 2022 |
CYRX / CryoPort Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Cryoport Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 229050307 (CUSIP Number) Eddie C. Brown Brown Capital Managem |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 CRYOPORT, INC. |
|
| August 4, 2022 |
Cryoport Reports Results for the Second Quarter 2022 Exhibit 99.1 Cryoport Reports Results for the Second Quarter 2022 ? Record revenue of $64.2 million for the quarter, up 14% as reported and 18% at constant currency (year-over-year) ? Supporting a record 626 global clinical trials; a net of 17 new trials added during the quarter ? Opened first two Global Supply Chain Centers, which include BioServices, in June 2022 ? Expanded global footprint into |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM SD Specialized Disclosure Report CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) Cryoport, Inc. 112 Westwood Place, Suite 350 Brentwood, TN 37027 (Add |
|
| May 27, 2022 |
EXHIBIT 1.01 Cryoport Inc. Conflict Minerals Report for the Year Ended December 31, 2021 This report for the year ended December 31, 2021 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the ?Rule?). The Rule was adopted by the Securities and Exchange Commission (the ?SEC?) to implement reporting and disclosure requirements related to conflict minerals |
|
| May 5, 2022 |
Cryoport Reports First Quarter 2022 Results Exhibit 99.1 Cryoport Reports First Quarter 2022 Results § Revenue of $52.3 million § Provides Full Year 2022 Revenue Guidance of $260-$265 million § Expansion and advancement of robust clinical pipeline continues – now supporting a record 609 clinical trials, with Phase 3 clinical trials increasing from 69 to 81 year over year § Cash and short-term investments of $600 million NASHVILLE, Tennessee |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 CRYOPORT, INC. |
|
| May 5, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 CRYOPORT, INC. |
|
| March 21, 2022 |
Employment Agreement dated March 15, 2022 between Cryoport, Inc. and Mark Sawicki. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into effective as of March 15, 2022 (the ?Effective Date?) by and between Cryoport, Inc., a Nevada corporation (the ?Company?), and Mark Sawicki (?Executive?). The Company and Executive are hereinafter collectively referred to as the ?Parties,? and individually referred to as a ?Party.? RECITALS A. Ex |
|
| March 21, 2022 |
Exhibit 10.2 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (the ?Second Amendment?) is made and entered into effective as of March 15, 2022 (the ?Amendment Date?) by and between Cryoport, Inc., a Nevada corporation (the ?Company?), and Jerrell W. Shelton (?Executive?), a resident of Tennessee. The Company and Executive are hereinafter collectively referred to as the ?Parties,? and |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 CRYOPORT, INC. |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant?? Filed by a Party other than the Registrant??? Check the appropriate box: ?? ? Preliminary Proxy Statement ?? ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? ? Definitive Pr |
|
| March 18, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statements ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ?? Definitive Additional Materials ?? Soliciting Material Pursuant to ?240. |
|
| March 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 CRYOPORT, INC. |
|
| March 11, 2022 |
Exhibit 99.1 Cryoport Authorizes $100 Million Repurchase Program - Management Presenting at Upcoming Investor Conferences NASHVILLE, Tennessee, March 11, 2022 - Cryoport, Inc. (NASDAQ: CYRX) (?Cryoport? or the ?Company?), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has unanimously authorized a repurchase pr |
|
| March 10, 2022 |
CYRX / CryoPort Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* Cryoport Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 229050307 (CUSIP Number) Eddie C. Brown Brown Capital Managem |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2022 |
EXHIBIT 21 SUBSIDIARIES OF CRYOPORT, INC. AND JURISDICTION OF INCORPORATION OR ORGANIZATION Cryogene, Inc. Texas Cryoport Systems, LLC California MVE Biological Solutions US, LLC Delaware Cryoport Netherlands BV The Netherlands Cryoport Japan GK Japan Cryoport UK Limited United Kingdom MVE Biological Solutions Australia Pty Limited Australia MVE Biological Solutions Germany GmbH Germany MVE Cryoge |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 CRYOPORT, INC. |
|
| February 24, 2022 |
Cryoport Reports Fourth Quarter and Full Year 2021 Results Exhibit 99.1 Cryoport Reports Fourth Quarter and Full Year 2021 Results ? 2021 annual revenue grew to $222.6 million, representing 183% year-over-year growth ? Cryoport Systems and CRYOGENE revenue grew 34% year-over-year for the fourth quarter ? Enters 2022 with $629 million in cash and short-term investments ? Expansion and advancement of robust clinical pipeline continues ? now supporting a rec |
|
| February 9, 2022 |
Exhibit 99.1 Cryoport Provides Positive Update on MVE Biological Solution?s New Prague Facility Production Expected to Resume Week of February 14, 2022 NASHVILLE, Tennessee, February 9, 2022 - Cryoport, Inc. (Nasdaq: CYRX) (?Cryoport? or the ?Company?), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today provided an update on resumption of activit |
|
| February 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 CRYOPORT, INC. |
|
| February 9, 2022 |
CYRX / CryoPort Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CryoPort Inc (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 9, 2022 |
CYRX / CryoPort Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: CryoPort Inc. Title of Class of Securities: Common Stock CUSIP Number: 229050307 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 CRYOPORT, INC. |
|
| February 1, 2022 |
Cryoport Reports Fire Damage at MVE’s New Prague Facility Exhibit 99.1 Cryoport Reports Fire Damage at MVE’s New Prague Facility NASHVILLE, Tennessee, January 31, 2022 - Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today reports that on January 25, 2022, a fire occurred at the MVE Biological Solutions manufacturing facility located in New Prag |
|
| January 10, 2022 |
CYRX / CryoPort Inc / ALGER ASSOCIATES INC - CRYOPORT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Cryoport, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 18, 2021 |
CYRX / CryoPort Inc / Blackstone Holdings III L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cryoport, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 229050307 (CUSIP Number) John G. Finley Blackstone Inc. 345 Park Avenue New York, New York 10154 Tel: (212) 583-5000 with a copy to: Anthony |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 12, 2021 |
Exhibit 4.1 EXECUTION VERSION CRYOPORT, INC. and U.S. Bank National Association as Trustee INDENTURE Dated as of November 12, 2021 0.75% Convertible Senior Notes due 2026 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions. 1 Section 1.02. Other Definitions. 12 Section 1.03. Rules of Construction. 13 Article 2. The Notes 14 Section 2.01. Form, Dating an |
|
| November 12, 2021 |
CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-251354? CALCULATION OF REGISTRATION FEE? ? Title of Each Class of Securities Offered ? ? Amount to be Registered ? ? Maximum Offering Price Per Unit ? ? Maximum Aggregate Offering Price ? ? Amount of Registration Fee(1) ? Common Stock, $0.001 par value per share ? ? ? ? 3,072,038 ? ? ? ? $ 81.10 ? ? ? ? $ 249,142,281.80 ? ? |
|
| November 10, 2021 |
PRICING TERM SHEET November 9, 2021 Cryoport, Inc. Placement of 3,072,038 shares of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 10, 2021 |
Cryoport, Inc. Prices Upsized $350.0 Million Convertible Senior Notes Offering Exhibit 99.1 Cryoport, Inc. Prices Upsized $350.0 Million Convertible Senior Notes Offering NASHVILLE, TENNESSEE?(PR NEWSWIRE)?November 9, 2021?Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the pricing of its offering of $350,000,000 aggregate principal amount of 0.75% convertible senior notes due 202 |
|
| November 10, 2021 |
Cryoport, Inc. Prices Registered Direct Placement of Common Stock Exhibit 99.2 Cryoport, Inc. Prices Registered Direct Placement of Common Stock NASHVILLE, TENNESSEE?(PR NEWSWIRE)?November 9, 2021?Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the pricing of its registered direct placement of 3,072,038 shares of common stock, at a price of $81.10 per share, in a dire |
|
| November 8, 2021 |
Cryoport, Inc. Announces Proposed Registered Direct Placement of Common Stock Exhibit 99.2 Cryoport, Inc. Announces Proposed Registered Direct Placement of Common Stock NASHVILLE, TENNESSEE?(PR NEWSWIRE)?November 8, 2021?Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its intention to offer, subject to market and other conditions, shares of its common stock in a direct placement |
|
| November 8, 2021 |
Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering NASHVILLE, TENNESSEE?(PR NEWSWIRE)?November 8, 2021?Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its intention to offer, subject to market and other conditions, $300,000,000 aggregate principal amount of convertible seni |
|
| November 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 8, 2021 |
SUBJECT TO COMPLETION, DATED NOVEMBER 8, 2021 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 4, 2021 |
Cryoport Reports Record Third Quarter and Nine Months Revenue for 2021 Exhibit 99.1 Cryoport Reports Record Third Quarter and Nine Months Revenue for 2021 ? Third quarter revenue increased 407% year over year, reaching $56.7 million; Nine Months 2021 revenue $166.2 million ? Organic Revenue Growth of 38% coupled with continuing strong performance by MVE Biological Solutions and CRYOPDP ? Now supporting a record 582 clinical trials and eight commercial therapies in re |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 CRYOPORT, INC. |
|
| August 26, 2021 |
CYRX / CryoPort Inc / Blackstone Holdings III L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cryoport, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 229050307 (CUSIP Number) John G. Finley Blackstone Inc. 345 Park Avenue New York, New York 10154 Tel: (212) 583-5000 with a copy to: Anthony F. Vernac |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2021 |
Cryoport Reports Record Second Quarter 2021 Revenue Exhibit 99.1 Cryoport Reports Record Second Quarter 2021 Revenue ? Record Revenue for Second Quarter of 2021 of $56.2 million ? Revenue increased 498% year over year, with continuing strong performance by MVE Biological Solutions and CRYOPDP ? Organic Revenue Growth of 55% ? Supporting a record 561 clinical trials and eight commercial therapies in regenerative medicine NASHVILLE, Tennessee, August |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 CRYOPORT, INC. |
|
| June 24, 2021 |
As filed with the Securities and Exchange Commission on June 24, 2021 As filed with the Securities and Exchange Commission on June 24, 2021 Registration No. |
|
| May 28, 2021 |
EXHIBIT 1.01 Cryoport Inc. Conflict Minerals Report for the Year Ended December 31, 2020 This report for the year ended December 31, 2020 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the ?Rule?). The Rule was adopted by the Securities and Exchange Commission (the ?SEC?) to implement reporting and disclosure requirements related to conflict minerals |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM SD Specialized Disclosure Report CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) Cryoport, Inc. 112 Westwood Place, Suite 350 Brentwood, TN 37027 (Add |
|
| May 6, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 5, 2021 |
Exhibit 10.1 Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended by the First Amendment and the Second Amendment, effective April 30, 2021) ARTICLE 1 ESTABLISHMENT, PURPOSE, EFFECTIVE DATE, EXPIRATION DATE 1.1 Establishment; Impact on Prior Plans. Cryoport, Inc. (the ?Company?) hereby establishes the ?Cryoport, Inc. 2018 Omnibus Equity Incentive Plan? (the ?Plan?). The Plan will supersed |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 CRYOPORT, INC. |
|
| May 4, 2021 |
Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021 Exhibit 99.1 Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021 ? Revenue increased 445% compared with Q1 2020, with acquisitions of MVE Biological Solutions and CRYOPDP driving significant growth ? Organic revenue growth of 35% compared with Q1 2020 ? A record 543 clinical trials in regenerative medicine are supported by Cryoport ? Cryoport now supports seven commercial therapies, in |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 CRYOPORT, INC. |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 16, 2021 |
Definitive Proxy Statement on Schedule 14A as filed with the SEC on March 16, 2021; ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Definitive Proxy Sta |
|
| March 3, 2021 |
Exhibit 99.1 Cryoport Announces Appointment of Linda Baddour to its Board of Directors Ms. Baddour brings over twenty years of experience across healthcare, life sciences and pharmaceuticals NASHVILLE, Tennessee, March 3, 2021 - Cryoport, Inc. (NASDAQ: CYRX) (?Cryoport? or the ?Company?), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announc |
|
| March 3, 2021 |
Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended by the First Amendment) Exhibit 10.1 Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended by the First Amendment effective February 25, 2021) ARTICLE 1 ESTABLISHMENT, PURPOSE, EFFECTIVE DATE, EXPIRATION DATE 1.1 Establishment; Impact on Prior Plans. Cryoport, Inc. (the ?Company?) hereby establishes the ?Cryoport, Inc. 2018 Omnibus Equity Incentive Plan? (the ?Plan?). The Plan will supersede and replace the Cryop |
|
| March 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 CRYOPORT, INC. |
|
| March 1, 2021 |
Cryoport Reports Record Results for Full Year 2020 Exhibit 99.1 Cryoport Reports Record Results for Full Year 2020 § Fourth quarter revenue increased 423% to $48.4 million, annual revenue increased 132% to $78.7 million § Organic growth in revenue was 36% for the fourth quarter and 26% for the full year 2020 § Cryoport is supporting a total of 528 clinical trials, and six commercial therapy agreements, including the global launch of Bristol-Myers |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 1, 2021 |
Exhibit 10.8 Cryoport, Inc. 2018 Omnibus Equity Incentive Plan NOTICE OF GRANT OF RESTRICTED STOCK RIGHTS (EMPLOYEE FORM) This Restricted Stock Right Agreement consists of this Notice of Grant of Restricted Stock Rights (the ?Grant Notice?) and the Restricted Stock Right Award Agreement immediately following. The Restricted Stock Right Agreement sets forth the specific terms and conditions governi |
|
| March 1, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 1, 2021 |
Exhibit 10.6 Cryoport, Inc. 2018 Omnibus Equity Incentive Plan NOTICE OF GRANT OF INCENTIVE STOCK OPTIONS This Incentive Stock Option Agreement consists of this Notice of Grant of Incentive Stock Options (the ?Grant Notice?) and the Incentive Stock Option Award Agreement immediately following. The Incentive Stock Option Agreement sets forth the specific terms and conditions governing Incentive Sto |
|
| March 1, 2021 |
? EXHIBIT 21 ? SUBSIDIARIES OF CRYOPORT, INC. AND JURISDICTION OF INCORPORATION OR ORGANIZATION ? Cryogene, Inc. Texas Cryoport Systems, LLC California MVE Biological Solutions US, LLC Delaware Cryoport Netherlands BV The Netherlands Cryoport Japan GK Japan Cryoport UK Limited United Kingdom MVE Biological Solutions Australia Pty Limited Australia MVE Biological Solutions Germany GmbH Germany MVE |
|
| March 1, 2021 |
Exhibit 10.7 Cryoport, Inc. 2018 Omnibus Equity Incentive Plan NOTICE OF GRANT OF NON-QUALIFIED STOCK OPTIONS (EMPLOYEE FORM) This Non-Qualified Stock Option Agreement consists of this Notice of Grant of Non-Qualified Stock Options (the ?Grant Notice?) and the Non-Qualified Stock Option Award Agreement immediately following. The Non-Qualified Stock Option Agreement sets forth the specific terms an |
|
| March 1, 2021 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Cryoport, Inc. (?we,? ?us,? ?Cryoport? or the ?Company?) had the following classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (i) common stock, $0.001 par value per share (?Co |
|
| February 16, 2021 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd., as the ultimate parent company of each of its undersigned subsidiarie |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cryoport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CryoPort Inc (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: CryoPort Inc. Title of Class of Securities: Common Stock CUSIP Number: 229050307 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 8, 2021 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2021 CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 8, 2021 |
Blackstone Converts $51 million of Cryoport Series C Preferred Stock Into Common Stock Exhibit 99.1 Blackstone Converts $51 million of Cryoport Series C Preferred Stock Into Common Stock NASHVILLE, Tenn., February 8, 2021 - Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that funds affiliated with Blackstone Tactical Opportunities (NYSE: BX) (“Blackstone”), e |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cryoport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cryoport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 25, 2021 |
Exhibit 1.1 Execution Version 3,787,878 Shares CRYOPORT, INC COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENT January 20, 2021 January 20, 2021 Morgan Stanley & Co. LLC Jefferies LLC SVB Leerink LLC UBS Securities LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC 1301 6th Avenue, |
|
| January 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 22, 2021 |
CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-251354 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.001 par value per share 4,356,059 $ 66.00 $ 287,499,894 $ 31,366.24 (1) Includes 568,181 shares of common st |
|
| January 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 CRYOPORT, INC. |
|
| January 20, 2021 |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Exhibit 99.1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Exhibit 99.1 contains forward-looking statements that have been made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. In some cas |
|
| January 19, 2021 |
Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 CRYOPORT, INC. |
|
| January 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 19, 2021 |
© 2021 Cryoport, Inc. All Rights Reserved CYRX: NASDAQ Exhibit 99.1 © 2021 Cryoport, Inc. All Rights Reserved CYRX: NASDAQ © 2021 Cryoport, Inc. All Rights Reserved Forward Looking Statements Statements in this presentation and statements made orally during this presentation are not purely historical, including statements regarding Cryoport’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are |
|
| January 19, 2021 |
SUBJECT TO COMPLETION, DATED JANUARY 19, 2021 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| December 15, 2020 |
Exhibit 25.2 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ¨ U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer Identif |
|
| December 15, 2020 |
Exhibit 4.20 CRYOPORT, INC. INDENTURE Dated as of , 20 U.S. BANK NATIONAL ASSOCIATION as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 5 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series 6 |
|
| December 15, 2020 |
Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ¨ U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer Identif |
|
| December 15, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 15, 2020 Registration No. |
|
| December 14, 2020 |
Exhibit 99.4 CHART CRYOBIOLOGICAL STORAGE (A Component of the Distribution & Storage Western Hemisphere Segment of Chart Industries, Inc.) Unaudited Condensed Combined Financial Statements as of September 30, 2020 and December 31, 2019 and the Nine Months Ended September 30, 2020 and 2019 CHART CRYOBIOLOGICAL STORAGE (A Component of the Distribution & Storage Western Hemisphere Segment of Chart In |
|
| December 14, 2020 |
Cryoport, Inc. and Subsidiaries Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.1 Cryoport, Inc. and Subsidiaries Unaudited Pro Forma Condensed Combined Financial Information CRYOPDP Acquisition On October 1, 2020, Cryoport, Inc. (the “Company” or “Cryoport”) completed its acquisition of CRYOPDP for a cash consideration of €49 million, subject to cash, net debt, working capital and other adjustments (the “CRYOPDP Acquisition”). This acquisition was funded with exis |
|
| December 14, 2020 |
Exhibit 99.2 CHART CRYOBIOLOGICAL STORAGE (A Component of the Distribution & Storage Western Hemisphere Segment of Chart Industries, Inc.) Combined Financial Statements as of and for the Years Ended December 31, 2019 and 2018 CHART CRYOBIOLOGICAL STORAGE (A Component of the Distribution & Storage Western Hemisphere Segment of Chart Industries, Inc.) INDEX Page Combined Financial Statements of Char |
|
| December 14, 2020 |
Exhibit 99.5 Advanced Therapy Logistics and Solutions Group « ATLAS » Consolidated IFRS Financial Statements September 30, 2020 (Expressed in Euros) 1 Summary Consolidated Statement of Financial Position 3 Consolidated Statement of Income 4 Income and comprehensive income 4 Consolidated Statement of Cash Flows 5 Consolidated Statement of Changes in Shareholders’ Equity 6 Notes to the Consolidated |
|
| December 14, 2020 |
Financial Statements and Exhibits - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| December 14, 2020 |
Consolidated IFRS Financial Statements December 31, 2019 (Expressed in Euros) Exhibit 99.3 CRYOPDP Consolidated IFRS Financial Statements December 31, 2019 (Expressed in Euros) 1 Sommaire Independent auditor’s report 3 Consolidated Statement of Financial Position 5 Consolidated Statement of Income 6 Income and comprehensive income 6 Consolidated Statement of Cash Flows 7 Consolidated Statement of Changes in Shareholders’ Equity 8 Notes to the Consolidated Financial Statemen |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| November 5, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 CRYOPORT, INC. |
|
| November 5, 2020 |
Cryoport Reports 2020 Third-Quarter Results Exhibit 99.1 Cryoport Reports 2020 Third-Quarter Results · Acquired MVE Biological Solutions and CRYOPDP advancing Cryoport’s position as the global leader in temperature-controlled supply chain solutions for the life sciences industry · Renewed contract to support Novartis’ commercial and clinical programs · Selected to support potential commercial launch of Bristol Myers Squibb’s Lisocabtagene M |
|
| October 13, 2020 |
EX-99.A Exhibit A JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, r |
|
| October 13, 2020 |
CYRX / CryoPort, Inc. / Blackstone Holdings III L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Cryoport, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 229050307 (CUSIP Number) John G. Finley The Blackstone Group Inc. 345 Park Avenue New York, New York 10154 Tel: (212) 583-5000 with a copy to: A |
|
| October 1, 2020 |
Exhibit 99.1 Cryoport Completes Acquisitions of MVE Biological Solutions and CRYOPDP Cryoport fortifies its position as a leading global provider of temperature-controlled life sciences solutions with a combined revenue run rate of over $160 million Blackstone invests $275 million NASHVILLE, Tennessee, October 1, 2020 - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the life sciences |
|
| October 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 1, 2020 |
Exhibit 3.1 Cryoport, Inc. Certificate of Designation 4.0% Series C Convertible Preferred Stock October 1, 2020 Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 10 Section 3. The Convertible Preferred Stock 11 (a) Designation; Par Value 11 (b) Number of Authorized Shares 11 (c) Form, Dating and Denominations 11 (d) Execution, Countersignature and Delivery 12 (e) Met |
|
| October 1, 2020 |
Exhibit 10.2 AMENDMENT N°1 TO THE SECURITIES PURCHASE AGREEMENT WITH RESPECT TO ADVANCED THERAPY LOGISTICS AND SOLUTIONS SAS This amendment n°1 to the securities purchase agreement with respect to Advanced Therapy Logistics And Solutions SAS dated as of August 21st, 2020 (the “Amendment Agreement”) is entered into by and between: (1) Cryoport, Inc., a corporation organized under the laws of the St |
|
| October 1, 2020 |
Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT BY AND BETWEEN CRYOPORT, INC. AND BLACKSTONE FREEZE PARENT L.P. Dated as of October 1, 2020 TABLE OF CONTENTS Page Article I Resale Shelf Registration 1 Section 1.1 Resale Shelf Registration Statement 1 Section 1.2 Effectiveness Period 2 Section 1.3 Subsequent Shelf Registration 2 Section 1.4 Supplements and Amendments 3 Section 1.5 Subsequent Holder Noti |
|
| August 25, 2020 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT BY AND BETWEEN CRYOPORT, INC., AND BTO FREEZE PARENT L.P. Dated as of August 24, 2020 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE OF PURCHASED SHARES 1 Section 1.1 Purchase and Sale 1 Section 1.2 Closing 1 ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE COMPANY 2 Section 2.1 Organization and Power 2 Section 2.2 Authorization; No |
|
| August 25, 2020 |
Exhibit 99.1 SCIENCE. LOGISTICS. CERTAINTY. Aug 25, 2020 Cryoport Announces Agreement to Acquire MVE Biological Solutions from Chart Industries Cryoport will become a leading global provider of cryogenic life sciences solutions Acquisitions of MVE, along with CRYOPDP is expected to increase Cryoport's revenue run rate to over $160 million and to be immediately accretive Blackstone to invest $275 m |
|
| August 25, 2020 |
Investor Presentation posted by Cryoport, Inc., dated August 25, 2020. Exhibit 99.2 |
|
| August 25, 2020 |
Exhibit 2.1 Execution Version PURCHASE AGREEMENT by and between CHART INDUSTRIES, INC. and CRYOPORT, INC. Dated as of August 24, 2020 TABLE OF CONTENTS PAGE Article I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Interpretive Matters 22 Article II PURCHASE AND SALE; PURCHASE PRICE 23 Section 2.1 Purchased Interests 23 Section 2.2 Acquired Assets and Assumed Liabilities 23 Section 2.3 Local A |
|
| August 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2020 CRYOPORT, INC. (Exact name of registrant as specified in its charter) Nevada 001-34632 88-0313393 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 21, 2020 |
Exhibt 10.1 20 August 2020 (1) Cryoport INC., as Purchaser (2) Each of the Sellers identified herein SECURITIES PURCHASE AGREEMENT with respect to the Securities of Advanced Therapy Logistics and Solutions SAS En accord avec les parties, les présentes ont été reliées par le procédé ASSEMBLACT R.C. empêchant toute substitution ou addition et sont seulement signées à la dernière page CONTENTS 1. Int |
|
| August 21, 2020 |
Exhibit 99.1 Cryoport Expands Global Supply Chain Platform by Signing Agreement to Acquire CRYOPDP Acquisition will expand Cryoport’s presence in both the EMEA and APAC regions and broaden Cryoport's range of temperature-controlled supply chain solutions for the life sciences; Upon closing, the acquisition is expected to be immediately accretive to earnings. NASHVILLE, Tennessee, August 21, 2020 - |
|
| August 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2020 CRYOPORT, INC. |
|
| August 10, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001 |
|
| August 7, 2020 |
Exhibit 99.1 Cryoport Reports 2020 Second-Quarter Results Revenue from commercial therapies increased 38% over the prior year 26 net clinical trial adds, now supporting 491 clinical trials in Regenerative Medicine market NASHVILLE, Tennessee (August 6, 2020) - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), a global leader in life sciences supply chain solutions, today announced financial results for |
|
| August 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 CRYOPORT, INC. |
|
| May 27, 2020 |
EXHIBIT 4.1 EXECUTION VERSION CRYOPORT, INC. and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of May 26, 2020 3.00% Convertible Senior Notes due 2025 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 8 Section 1.03. Rules of Construction 9 Article 2. The Notes 10 Section 2.01. Form, Dating and Denomina |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2020 CRYOPORT, INC. |
|
| May 27, 2020 |
Exhibit 10.1 Execution Copy REGISTRATION RIGHTS AGREEMENT May 26, 2020 JEFFERIES LLC SVB LEERINK LLC As Representatives of the Initial Purchasers listed in Schedule I to the Purchase Agreement c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC 1301 6th Avenue, 12th Floor New York, New York 10019 Ladies and Gentlemen: Cryoport, Inc., a Nevada corporation (the “Company |
|
| May 21, 2020 |
Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering EXHIBIT 99.1 Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering NASHVILLE, Tennessee—(PRNewswire)—May 19, 2020—Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”) today announced its intention to offer, subject to market and other conditions, $100.0 million in aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private offering to investors reasonably believe |
|
| May 21, 2020 |
Cryoport, Inc. Prices $100.0 Million Convertible Senior Notes Offering EXHIBIT 99.2 Cryoport, Inc. Prices $100.0 Million Convertible Senior Notes Offering NASHVILLE, Tennessee—(PRNewswire)—May 21, 2020—Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”) today announced the pricing on May 20, 2020 of its offering of $100.0 million in aggregate principal amount of 3.00% convertible senior notes due 2025 (the “notes”) in a private offering to investors reasonably believed to be |
|
| May 21, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2020 CRYOPORT, INC. |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34632 CRYOPORT, |
|
| May 8, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| May 8, 2020 |
Exhibit 99.1 Cryoport Revenue Grows 47% for First Quarter 2020 - Revenue from commercial therapies increased 110% over the prior year 29 clinical trials added, now supporting 465 clinical trials in Regenerative Medicine market NASHVILLE, Tennessee, May 7, 2020 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport”), a global leader in life sciences solutions, today announced financial results |
|
| May 7, 2020 |
Exhibit 99.1 Cryoport Revenue Grows 47% for First Quarter 2020 - Revenue from commercial therapies increased 110% over the prior year 29 clinical trials added, now supporting 465 clinical trials in Regenerative Medicine market NASHVILLE, Tennessee, May 7, 2020 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport”), a global leader in life sciences solutions, today announced financial results |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 CRYOPORT, INC. |
|
| May 5, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2020 CRYOPORT, INC. |
|
| April 3, 2020 |
CYRX / CryoPort, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) x Definitive Proxy State |
|
| March 10, 2020 |
CYRX / CryoPort, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34632 CRYOPORT, INC. |
|
| March 10, 2020 |
Description of the Company's securities. EXHIBIT 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Cryoport, Inc. (“we,” “us,” “Cryoport” or the “Company”) had the following classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.001 par value per share (“Co |
|
| March 10, 2020 |
EXHIBIT 21 CRYOPORT, INC. SUBSIDIARIES OF REGISTRANT Cryoport Systems, Inc. Cryoport Netherlands B.V. Cryoport UK Limited Cryogene, Inc. |
|
| March 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2020 CRYOPORT, INC. |
|
| March 5, 2020 |
EX-99.1 2 tm2011779d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Record Revenue for Fiscal Year 2019 - Revenue grows 73% year over year Revenue from commercial therapies increased 295% over the prior year to $8.3 million Cryoport now supports 436 clinical trials in Regenerative Medicine marke NASHVILLE, Tennessee, March 5, 2020 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport”) |
|
| March 3, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| February 14, 2020 |
CYRX / CryoPort, Inc. / Alger Associates Inc - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cryoport, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2020 |
CYRX / CryoPort, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: CryoPort Inc Title of Class of Securities: Common Stock CUSIP Number: 229050307 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1 |
|
| January 31, 2020 |
CYRX / CryoPort, Inc. / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cryoport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 229050307 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 9, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 CRYOPORT, INC. |
|
| January 9, 2020 |
Exhibit 99.1 Cryoport Announces Preliminary Fourth Quarter and Full Year 2019 Revenue - 2019 Revenue Grows 73%, BioPharma Revenue Grows 64% NASHVILLE, Tennessee, January 9th, 2020 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport”), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced preliminary revenue for the twelve and t |
|
| December 19, 2019 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2019 CRYOPORT, INC. |
|
| November 12, 2019 |
CYRX / CryoPort, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 CRYOPORT, INC. |
|
| November 7, 2019 |
EX-99.1 2 tm1919571d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Revenue Grows 81% for Third Quarter 2019 - Cryoport now supports 425 clinical trials in Regenerative Medicine market Revenue from commercial therapies increased 368% over same quarter last year and 39% sequentially IRVINE, California, November 7, 2019 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport”), the world's leading |
